Search for a trial

A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers.

Primary Objectives- To evaluate disease related characteristics in patients with different vulvar conditions compared to healthy volunteers - To evaluate the variability of the selected biomarkers between subjects, and within subjects over time.…

FIGO 2018 stage IB2 (>2cm - <=4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy
Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative
Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F)

This study has been transitioned to CTIS with ID 2023-507230-24-00 check the CTIS register for the current data. To assess the feasibility of preserving fertility in women with 2018 FIGO stage IB2 cervical cancer with lesions measuring &gt;2 cm…

Isolation and immune profiling of human B lymphocytes for the development of potential diagnostic and therapeutic antibodies

We aim to study B cells derived from tumor and peripheral blood of uterine cancer patients in order to evaluate B cell-produced (tumor binding) antibodies for potential diagnostic and therapeutic interventions.

A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia.

The primary objective of this trial is to determine clinical efficacy of Vvax001 in CIN3 patients.

The RACC trial -Robot-assisted Approach to Cervical Cancer. A multi-centre open-label randomised non-inferiority trial of robotassisted laparoscopic surgery versus laparotomy in women with early stage cervical cancer.

We aim to demonstrate that robot-assisted laparoscopic radical hysterectomy is non-inferior to conventional laparotomy in recurrence free survival of patients with early stage cervical cancer (stage 1B1, 1B2 and 2A1).

An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (DCP-001) in high grade serous ovarian cancer patients after primary treatment

This study has been transitioned to CTIS with ID 2024-516781-10-00 check the CTIS register for the current data. Primary objective:• Systemic immunogenicity of the DCP-001 vaccination in high grade serous ovarian (HGSOC) cancer patients.